Published on 21/12/2025

How to Effectively Address Site Questions and Concerns During SIV

A successful Site Initiation Visit (SIV) is not just about reviewing regulatory documents and conducting protocol training—it’s also about creating an open and responsive environment for the clinical site team to ask questions and raise concerns. Proactively managing these inquiries improves site engagement, ensures clarity on protocol expectations, and lays the foundation for strong sponsor-site collaboration throughout the study. In this guide, we outline how clinical research associates (CRAs), sponsors, and CROs can address site queries effectively during SIV.

Table of Contents

Why Site Questions Matter During SIV

Site questions signal active engagement. When investigators or study coordinators raise concerns, it’s an opportunity to:

Clarify misunderstandings before enrollment begins
Improve protocol compliance and GCP adherence
Identify site-specific needs or resource gaps
Foster trust and transparency with the sponsor/CRO

Ignoring or deflecting these questions may result in errors during subject recruitment or data collection.

Types of Questions Commonly Raised During SIV

Below are typical categories of site questions encountered during SIV:

1. Protocol-Specific Clarifications

Eligibility criteria complexities (e.g., lab value thresholds, age cutoffs)
Clarification on prohibited medications or washout periods
Timing of assessments and visit windows

2. Informed Consent and Ethics Queries

ICF version control and re-consenting policies
Language requirements and translation approvals
Consent process for illiterate or vulnerable subjects

3. Investigational Product

(IP) Concerns

Drug storage temperature range and excursions
Accountability logs and return process
Emergency unblinding protocol

4. Data Entry and EDC Issues

Access to EDC/IWRS systems
Timelines for data entry and query response
Handling missing data or outliers

5. Monitoring and Communication Protocols

CRA visit frequency and remote access procedures
Escalation pathway for urgent issues
Expectations for pre-screening logs and recruitment updates

It’s crucial to be equipped with Pharma SOPs and site management tools to standardize how these queries are documented and responded to.

Best Practices for Responding to Site Questions

1. Encourage an Open Dialogue

Set the tone at the beginning of SIV that questions are welcome
Reassure site staff that it’s normal to seek clarification
Allocate time after each session for Q&A

2. Use a Question Tracker

Maintain a live document of all questions asked during the meeting
Include the responsible party for follow-up if the answer is not immediately available
File this tracker in the TMF/ISF as part of SIV documentation

3. Answer Precisely and with Regulatory Context

Where applicable, reference USFDA or EMA guidance
Link the explanation back to the protocol or GCP guideline
Avoid vague or tentative responses

4. Escalate Appropriately

If the question requires medical or sponsor-level input, escalate via designated communication pathways
Set a realistic timeline for response (e.g., within 3 business days)
Update the site once resolution is received

5. Provide Reference Materials

Use job aids, protocol cheat sheets, or flowcharts
Direct site staff to validated SOPs or training modules on Stability Studies
Store materials in a shared portal accessible post-SIV

Real-World Examples

Example 1: Protocol Misunderstanding

At an oncology site, the PI believed baseline imaging was optional. During SIV, the CRA clarified that imaging within 14 days of enrollment was mandatory. The protocol section and schedule of assessments were reviewed, preventing a potential protocol deviation.

Example 2: IP Storage Concern

A site pharmacy raised concern about lack of 24/7 temperature monitoring. The CRA provided options such as digital data loggers and alerted the sponsor, who approved an external monitoring vendor.

Tools to Facilitate Communication

Site Question Log Template
Protocol Summary One-Pager
Investigator FAQ Sheets
Communication SOPs aligned with GMP compliance

Conclusion

Proactively addressing site questions and concerns during the SIV can significantly improve site readiness, reduce protocol deviations, and foster a culture of trust and transparency. CRAs and sponsors should encourage open dialogue, provide structured follow-up, and maintain a robust documentation trail of all discussions. These efforts ensure alignment and operational excellence from study startup to closeout.